Document:

Amendment Agreement to the Collaboration Agreement, dated December 19, 2007

 Exhibit 10.58 
 CONFIDENTIAL TREATMENT REQUESTED UNDER 
 17 C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 240.24b-2.

 [*****] INDICATES OMITTED MATERIAL THAT IS THE 
 SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST 
 FILED SEPARATELY WITH THE COMMISSION. 
 THE OMITTED MATERIAL HAS BEEN FILED 
 SEPARATELY
WITH THE COMMISSION. 
 Amendment Agreement 
 This Amendment Agreement (“Agreement”) dated December 19, 2007 (the “Effective Date”) is by and between The Procter & Gamble Company, Procter & Gamble
Pharmaceuticals, Inc. (collectively, “P&G”) and Sanofi-Aventis U.S. LLC (“S-A”), (individually P&G and S-A may also be referred to herein as “Party” and collectively as the “Parties”). 
 WHEREAS, P&G and S-A (as successor in interest to Aventis Pharmaceuticals Inc.) are parties to an Amended and Restated Collaboration Agreement dated
October 8, 2004 (as subsequently amended, the “Collaboration Agreement”); and 
 WHEREAS, P&G and S-A desire to amend the
Collaboration Agreement to establish a process by which the Parties might restructure the commercialization efforts for the Product in certain European countries, to establish appropriate investment incentives in the period immediately prior to the
end of the Term, and to continue the development of ***** (as defined herein) as a Joint Product Improvement. Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in the Collaboration Agreement. 
 NOW, THEREFORE, in consideration of the mutual promises, covenants, and agreements hereinafter set forth the Parties to this Agreement hereby agree to amend
the terms and conditions of the Collaboration Agreement as follows: 
 1. European Simplification 
 The Parties agree that their respective rights and obligations with respect to the Product in the European countries of Belgium, Germany, Luxembourg, and The
Netherlands shall be revised as set forth in Exhibit A, attached to and made a part of this Agreement. For purposes of this Agreement and consistent with the Collaboration Agreement, the Parties acknowledge and agree that any reference to
“Belgium” in this Agreement shall include the same understanding for the country of Luxembourg. 
 2. Term Extension

 If on or prior to August 1, 2011 the Parties do not agree to an extension of the Term beyond January 1, 2015, then the following
provisions shall apply to all of the Territories under the Collaboration Agreement except the Potential Co-Promotion Territory which shall not be subject to the following and which shall continue to be subject to the terms of the Collaboration
Agreement: 
 A. Decision-making and Cost Sharing with Respect to Promotion Efforts and Marketing Efforts. P&G shall
have the right to make the final decision with respect to all matters regarding Promotion Efforts in the final three Contract Years of the Term (Contract Years 2012 to 2014); provided, that unless otherwise agreed by the Parties, S-A will not be
obligated to provide Promotion Efforts, nor to pay for the cost of Promotion Efforts or Marketing Efforts in such Contract Years 2012-2014 that may exceed the cost of the Promotion Efforts or Marketing Efforts for Contract Year 2011. 
 B. Decision-making and Cost Sharing with Respect to R&D Efforts. P&G shall have the final decision-making authority with
respect to all matters regarding R&D Efforts in the final three Contract Years of the Term (Contract Years from 2012 to 2014), including decisions regarding the allocation of FTEs in support of such R&D efforts; provided that, unless
otherwise mutually agreed, S-A shall not be obligated under Section III(G) of the Collaboration Agreement to pay for Joint R&D Costs during such Contract Years 2012-2014, except for those Joint R&D Costs related to ongoing
pharmacovigilance, regulatory, and medical support for Products already commercialized by the Parties that are solely necessary to satisfy regulatory obligations required to keep those Products on the market. 
  

 1 

 C. Change in the Marketplace for Product. In the event there is a Promotional
Potential Loss of Exclusivity, Promotional Actual Loss of Exclusivity, or a significant reduction in Net Outside Sales of the Product in a country or countries prior to Contract Year 2011, then the Parties shall discuss in good faith the eighteen
(18) month budget or other applicable budget for the cost of Promotion Efforts, Marketing Efforts, and Joint R&D Efforts in such country or countries for Contact Year 2011, consistent with the terms of Section III (G)(5) and III (J) of
the Collaboration Agreement. 
 3. ***** 
 A. R&D Cost Sharing. ***** as used in this Agreement shall mean the Product Improvement that as of the date hereof is being studied in the ***** clinical study conducted by P&G under
protocol number ***** . The Parties shall share R&D Costs for ***** as set forth in this Section 3.A. 
 1. Upfront
Payment. On or before December 21, 2007, in consideration for past development costs for *****, and as an inventor’s premium for P&G and in consideration for P&G contributing ***** to the Parties’ alliance for Actonel®
under the Collaboration Agreement, S-A shall pay to P&G a non-refundable payment of *****. 
 2. Adjustment Payment
Contingent on *****. If as a result of a decision or order from a U.S. federal court (whether a district or appellate court) pursuant to which any of *****, (collectively, the “Asserted Claims”) asserted at trial in the lawsuit
captioned as ***** is upheld as valid, S-A shall pay to P&G ***** within five (5) Business Days of such decision of the applicable U.S. federal court; provided that, if ***** thereafter appeals such decision of such U.S. federal
court, and if, as a result of a final and unappealable decision or order of a higher US federal court, all of the Asserted Claims are held not valid such that no valid, Asserted Claim covers a risedronate product that is the subject of *****, then
P&G shall refund such payment to S-A within five (5) Business Days of the later of: (a) such final, unappealable decision; or (b) marketing by ***** of a product under *****, or marketing by another third party of a product under
an ANDA or a 505(b)(2) application, in each case where such ANDA or 505(b)(2) application references *****. Any amount payable by a Party under this Section 3(A)(3) shall be included in the calculation of the global reimbursement payment, as
described in Section II(B) of the Collaboration Agreement, for the Quarter in which such payment becomes due. 
 3.
R&D Cost Sharing. Except as set forth in this Agreement, the rights and obligations of the Parties with respect to the research and development program for ***** shall be as set forth in the Collaboration Agreement, provided, however, the
equal sharing of the actual Joint R&D costs for the program shall be applicable from and after January 1, 2008 only. Any R&D FTEs provided by S-A for R&D Efforts for ***** must be approved by the R&D Committee, and if so
approved shall be shared and paid consistent with the terms of the Collaboration Agreement for R&D FTEs and Joint R&D Costs. 
 B.
Designation as Joint Product Improvement. ***** is hereby designated a Joint Product Improvement, and subject to the provisions of Section 3 of this Agreement, its further development shall be subject to the provisions of Section
XVIII(B) of the Collaboration Agreement. 
  

 2 

 C. Decision-making. Prior to the date that first year results at the primary statistical endpoint are
available from the hard locked database for the Phase III clinical study for ***** conducted by ***** P&G shall use commercially reasonable efforts to consult with S-A on decisions regarding the development of such Joint Product Improvement;
provided, that until such date P&G shall have the right in its sole discretion to make such decisions. On and after such date, decisions regarding the development of ***** shall be subject to the other provisions of the Collaboration Agreement
that are applicable to Joint Product Improvements. 
 Except as specifically agreed by the Parties herein, the Collaboration Agreement shall
remain in full force and effect. 
 IN WITNESS WHEREOF, the Parties hereto have caused this Amendment Agreement to the Collaboration Agreement
to be executed by their duly authorized representative(s) as of the Effective Date hereof. 
  

									
	By:	 	 /s/ Thomas M. Finn
	 		 	By:	 	 /s/ Jose Ferrer

		 	Thomas M. Finn	 		 		 	Jose Ferrer
		 	President, Global Health Care	 		 		 	Authorized Signatory
		 	The Procter & Gamble Company	 		 		 	Sanofi-Aventis U.S. LLC
					
	By:	 	 /s/ Thomas M. Finn
	 		 	By:	 	 /s/ Philippe Alaterre

		 	Thomas M. Finn	 		 		 	Philippe Alaterre
		 	Vice President,	 		 		 	Authorized Signatory
		 	Procter & Gamble Pharmaceuticals, Inc.	 		 		 	Sanofi-Aventis U.S. LLC

  

 3 

 Exhibit A 
 Western Europe Simplification 
 P&G and S-A agree that
their rights and obligations with respect to the Co-Promotion of Product in Belgium, Germany, Luxembourg, and the Netherlands, shall be revised as further described below. As noted previously in this Amendment Agreement, for purposes of this
Agreement, any reference to Belgium shall be applicable and shall include the country of Luxembourg: 
 1. Establishment of P&G
Promotion Territory. The Parties shall use reasonable efforts to enable P&G to assume full responsibility for management and execution of Promotional Efforts, Marketing Efforts and R&D Efforts in the following countries, on the dates
indicated or as soon as reasonably possible thereafter as mutually agreed by the Parties, and such countries upon P&G’s assumption of full responsibility shall be considered part of the “P&G Promotion Territory”: Germany,
Belgium and Luxembourg, on and after January 1, 2008; and The Netherlands, on and after April 1, 2008 or sooner if mutually agreed by the Parties. The Parties will in good faith continue discussions regarding the potential transfer of the
United Kingdom (the “UK”) to the P&G Promotion Territory in a manner and by means of a separate agreement that is generally consistent with the terms and conditions of this Exhibit A. Furthermore, if and when the Parties mutually agree
to include the UK in the P&G Promotion Territory, then (i) the provisions included in Section 4 of this Exhibit A with respect to expense sharing shall include the UK and the Investment Cap defined and further described in such
Section 4 shall include and be applicable to the promotion of Product in the UK, and substantially similar provisions with respect to expense sharing shall be incorporated in the definitive agreement between the Parties to include the UK in the
P&G Promotion Territory; and (ii) the provisions of Section 8 of this Exhibit shall apply to the UK and shall be incorporated in the definitive agreement between the Parties to include the UK in the P&G Promotion Territory. Unless
and until the Parties agree to include the UK in the P&G Promotion Territory, the following investment levels for Promotion Efforts and Marketing Efforts have been agreed to for the UK: for Contract Year 2008,*****; for Contract Year 2009,*****;
for Contract Year 2010,*****. 
 2. Management Structure. P&G shall maintain its own management and business operations and
develop, maintain and execute its own marketing, promotion, sales, distribution and R&D plans with respect to the Product within the P&G Promotion Territory and such plans need not be submitted to, nor approved by, S-A; provided that,
P&G shall provide to S-A the following for informational purposes: (a) a report which sets forth an indicative forecast of Net Outside Sales (“NOS”) for the P&G Promotion Territory, and such report will be provided three
(3) months prior to each Calendar Year; (b) a Quarterly report of actual NOS in the P&G Promotion Territory; (c) a Quarterly report of operating expenses (defined as the cost of Promotional Efforts and Marketing Efforts);
(d) a report of actual NOS for the previous Contract Year; (e) an annual osteoporosis market share report; and (f) three (3) months prior to the beginning of each Contract Year, a forecast budget for the cost of Promotion Efforts
and Marketing Efforts to be undertaken by P&G in the P&G Promotion Territory in such Contract Year. 
  

 4 

 3. Contribution Sharing: 
 With respect to the calculation of the global reimbursement payment set forth in Section II(B) of the Collaboration Agreement, the countries in the P&G Promotion Territory shall be included in
the Co-Promotion Territory, and the calculation and application of the Threshold Amount shall not change. 
 There shall be no restrictions on
P&G’s ability to engage Contract Representatives to perform Detailing Efforts in the P&G Promotion Territory. P&G shall not be obligated to perform a minimum level of Detailing Efforts, and no penalty payment shall be applicable to
Detailing Efforts in the P&G Promotion Territory. 
 4. Expense Sharing. 
 (a) General. With respect to the countries in the P&G Promotion Territory for each of Calendar Years 2008, 2009 and 2010, the Parties have agreed
to a maximum annual threshold or cap for the Investment Costs (for purposes of this Agreement, “Investment Costs” shall mean the costs related to and included in Promotion Efforts and Marketing Efforts that are included in the Quarterly
invoices and reimbursement calculated for the Co-Promotion Countries under the Collaboration Agreement as of the Effective Date of this Agreement) that may be incurred by P&G in the P&G Promotion Territory and shared equally by the Parties
as follows: (i) ***** of the total actual NOS for all countries in the P&G Promotion Territory in 2008; (ii) ***** of the total actual NOS for all countries in the P&G Promotion Territory in 2009; and (iii) ***** of the total
actual NOS for all countries in the P&G Promotion Territory in 2010 (the “Investment Cap”). Consistent with the terms of the Collaboration Agreement, the Parties shall share ***** the actual Investment Costs incurred by P&G in the
P&G Promotion Territory as part of the global reimbursement calculated pursuant to Schedule II (B) of the Collaboration Agreement, subject to the Investment Cap as further described in Subsection (b) immediately below. No later than
January 31, 2008, the Parties will in good faith discuss whether it is appropriate to include the cost of local R&D Efforts in the Investment Costs for countries in the P&G Promotion Territory, and whether it is appropriate to adjust
the Investment Caps accordingly; provided that, until the Parties agree otherwise, the terms and conditions of the Collaboration Agreement will prevail. 
 (b) Application of the Investment Cap. The following shall apply with regard to the Investment Cap: 
 (i) For each of Calendar Years 2008, 2009, and 2010, the Parties shall share ***** the lower of either the total actual Investment Costs incurred by P&G in all countries of the P&G
Promotion Territory in the applicable Calendar Year, or an amount equal to the corresponding Investment Cap for such Calendar Year. If the Investment Cap is applied in a given Calendar Year, then P&G shall be solely responsible for any of its
Investment Costs that exceed the amount equal to the Investment Cap for such Calendar Year; 
 (ii) If an event occurs that is
unusual and could not reasonably have been foreseen or anticipated by P&G, and where, in each instance, such event can reasonably be expected to substantially impact P&G’s ability to reasonably maintain its Investment Costs in the
P&G Promotion Territory below the Investment Cap in a particular Contract Year (the “Unusual Event”), then (x) as soon as reasonably practical, the Parties shall discuss potential reasonable solutions to address the Unusual Event
and P&G’s Investment Costs that exceed the Investment

  

 5 

 
Cap; (y) P&G shall take all reasonable actions to implement such mutually agreed solutions or to mitigate its Investment Costs in response to the Unusual Event, as applicable; and
(z) the Parties shall share ***** the actual Investment Costs incurred by P&G as a result of the Unusual Event, including those that may exceed the Investment Cap, for such time as P&G incurs such additional Investment Costs, but in no
event for longer than a period of three (3) consecutive months after the occurrence of the Unusual Event; and, 
 (iii) In
the event the Investment Cap is applied in a given Calendar Year as described in Subsection 4 (b)(i) above, then the Parties shall in good faith discuss the Investment Costs and Investment Cap anticipated for the subsequent Calendar Years after the
Calendar Year when the Investment Cap is applied, and may mutually agree to adjust the Investment Cap for the subsequent Calendar Years. 
 (c)
Calculation Under the Collaboration Agreement. Subject to the application of the Investment Cap in Section 4(b) above, the calculation of the Investment Costs for the P&G Promotion Territory shall be made as part of the calculation
for the global reimbursement consistent with Schedule II (B) of the Collaboration Agreement, and shall be included in such calculation under Schedule II (B) as if such Investment Costs were incurred in the Co-Promotion Territory.

 (d) Contract Year 2011 and Thereafter. For each Contract Year after 2010, three (3) months prior to January 1 of the
subsequent Calendar Year, the Parties will in good faith discuss and agree to an Investment Cap that reasonably reflects the market for the Product on a country by country basis for each country in the P&G Promotion Territory. Such discussion
shall include the factors reasonably affecting the market for the Product in each such country, including such factors as the marketing of generic versions of the Product by third parties, pediatric market exclusivity, and the pricing environment.

 (e) Investment Costs Incurred Prior to Inclusion of a Country in the P&G Promotion Territory. All expenses incurred in a
particular country prior to the date it is included in the P&G Promotion Territory pursuant to Section 1 of this Exhibit A, should be included in the final Quarterly true-up process for the Quarter in which such transfer occurs. Accrual
releases will be communicated by S-A to P&G, once final actual expenses are known and booked. 
 5. Modification of artwork,
packaging, labels: As applicable, the Parties will in good faith agree to a reasonable plan for the modification of any artwork or other packaging related to the Product in countries in the P&G Promotion Territory, to include a
reasonable phase-out of existing stock of such artwork and other packaging materials. 
 6. Global or Central activities (CMK, ER,
Marketing, Other activities): With respect to any effort at the global level that is performed in support of any country in the P&G Promotion Territory, such efforts will continue to be performed in the same manner. However, if mutually
agreed, the Parties may re-assign certain efforts and budgets included within the global effort against the efforts performed in certain countries of the P&G Promotion Territory; provided that, and any such reassigned efforts and/or
budgets shall be included in the mutually agreed budgets and the applicable Investment Cap(s) shall not be revised. 
  

 6 

 7. Transition Services: S-A will provide the transition services reasonably necessary to
enable the transition of countries into the P&G Promotion Territory, as generally described below, and as such services will be described more specifically in a definitive transition services agreement to be executed between the Parties on or
before February 29, 2008, or such other date as mutually agreed by the Parties. The costs and expenses related to the transition services for the P&G Promotion Territory incurred by either Party shall be shared *****. For clarification, to
the extent a Party incurs any costs related to the transition services in addition to the costs subject to the Investment Cap, such additional costs will not be shared and will be borne solely by the respective Party incurring such costs.

 Generally, S-A will provide the following transition services to facilitate the inclusion of Germany, The Netherlands and Belgium in the
Co-Promotion Territory, to countries in the P&G Promotion Territory: 
 (a) Germany: 
  

	 	•	 	 Share S-A’s key customer appointments and planned group selling events by December 31, 2007 

  

	 	•	 	 Share S-A’s information regarding the “High Potential Target Group” and key contact lists by December 31, 2007

  

	 	•	 	 Clarify which promotional materials and samples stored by Sanofi-Aventis Deutschland GmbH are requested by P&G and determine a process for to make
them available to P&G by December 31, 2007 (the transfer will take place on or before January 31, 2008) 

  

	 	•	 	 Other services reasonable, customary and necessary to facilitate the inclusion of Germany in the P&G Promotion Territory, including but not limited
to, the sharing of documents, making available samples, sales and promotional materials, and training materials, and as appropriate transferring ongoing non-interventional studies and clinical studies, grants, etc. on or before January
31st, 2008 

 (b) Belgium: 
  

	 	•	 	 S-A will continue its R&D Efforts related to management of ***** until March 31, 2008, and shall thereafter cooperate to transfer the
management of the ***** to P&G or its designee as determined by P&G. 

  

	 	•	 	 S-A will continue to provide reduced Promotional Efforts and Marketing Efforts (reduced to a level agreed by the Parties), until March 31, 2008,
and will facilitate the transfer of information related to its Promotional Efforts to P&G 

  

	 	•	 	 Other transition services reasonable, customary and necessary to facilitate the inclusion of Belgium into the P&G Promotion Territory including but
not limited to, the sharing of documents, making available samples, sales and promotional materials, and training materials, and as appropriate transferring any ongoing clinical studies, grants, etc. 

  

	 	•	 	 Agree to a plan for the handling of adverse events reports and medical communication requests for events that occur prior to January 1, 2008 and
after January 1, 2008 

  

 7 

 (c) Netherlands: 
  

	 	•	 	 S-A will reduce its Detailing in Efforts to ***** as of April 1, 2008 

  

	 	•	 	 Share S-A’s key customer appointments as of February 1, 2008 

  

	 	•	 	 S-A will continue to manage the ***** until March 31, 2008, and thereafter, shall cooperate to transfer the management of the ***** to P&G or
its designee, as determined by P&G. 

  

	 	•	 	 Transfer all archives and databases related to the *****, and the Parties (or their Affiliates as applicable) shall agree to a communication plan with
regard to the study investigators, and to finalize any abstracts and/or scientific journal articles related to the study. 

  

	 	•	 	 Transfer to P&G or its designee, all archives and databases related to the ***** and the *****, and the Parties (or their Affiliates as applicable)
shall agree to a communication plan with regard to the study investigators, and to finalize any abstracts or scientific journal articles related to the study. 

  

	 	•	 	 Transfer to P&G or its designee, all archives and databases related to the ***** and the ***** 

  

	 	•	 	 Other transition services reasonable, customary and necessary to facilitate the inclusion of The Netherlands in the P&G Promotion Territory,
including but not limited to, the sharing of documents, making available samples, sales and promotional materials, and training materials, and as appropriate transferring any other ongoing clinical studies, grants, etc. 

 

	 	•	 	 Agree to a plan for the handling of adverse events reports and medical communication requests for events that occurred prior to and after
January 1, 2008 

 8. Acquired Rights Directive. The Parties shall comply with their potential obligations
under the Council Directive 2001/23/EC and corresponding local laws (collectively, the “Directive), and where applicable, shall provide the information to each other which may be required under the Directive to reasonably consult with their
respective employees, and current or future suppliers of Services (as “Services” is defined immediately below). In a manner that is consistent with the foregoing obligation, S-A shall use its commercially reasonable efforts to treat its
respective employees involved in the Promotion Efforts, Marketing Efforts or R&D Efforts for the Product in Belgium, The Netherlands, Luxembourg or Germany (respectively the “Affected Employees,” and the “Services”), in a
manner that is commensurate with that used by S-A with respect to its other employees performing similar commercial or research and development services for other products with similar market potential or product life as Product, in S-A’s
pharmaceutical business (for example with respect to employees’ opportunities to transition their services to different products, the administration of severance packages, etc.), in order to limit or to mitigate the need for any of such
Affected Employees to avail themselves of their rights under the Directive. 
 In the event that after the Effective Date, any of the Affected
Employees makes a successful claim that its employment rights are protected as a result of a transfer of undertaking in accordance with the Directive, whether against P&G or a third party hired by P&G to perform any of the Services, S-A will
indemnify P&G for (i) the cost of salaries, benefits, and severance payments paid by P&G or such third parties to the Affected Employee that are substantially similar to and consistent with such amounts paid by S-A to such Affected
Employee on the date the Affected Employee makes his/her claim (or the date such Employee was last employed by S-A,

  

 8 

 
as applicable); (ii) any settlement costs related to such claims that are based upon the salaries, benefits, and severance payments, etc., paid by S-A on the date such Affected Employee
makes his/her claim; (iii) any costs found to be directly related to such claims by the Affected Employee and to other employees of P&G or such third parties, such as severance costs for employees displaced by Affected Employees; and
(iv) all reasonable administrative and legal costs directly related to the foregoing; provided that, (1) S-A shall only be obligated to indemnify P&G to the extent such costs described in subsections (i)-(iv) in the aggregate
exceed ***** and only for such amount in excess of *****; (2) the potential costs for the third party hired by P&G to perform the Services described herein will be included only to the extent P&G has a corresponding written contractual
obligation to indemnify such third party for such costs related to the Affected Employee; and (3) S-A shall not be obligated to indemnify P&G for such costs described in subsections (i)-(iv) that are incurred by P&G more than
twelve (12) months after the date the Affected Employee makes his/her claim under the Directive. 
 Prior to asserting any claim for
indemnification under this provision, P&G shall in good faith discuss such claim with S-A. Any amount payable by S-A under this Section 8 shall be included in the calculation of the global reimbursement payment, as described in
Section II(B) of the Collaboration Agreement, for the Quarter in which such costs are actually incurred by P&G. Furthermore, any potential amounts payable by S-A under this Section 8 of Exhibit A shall be subject to the provisions of
Sections XXI (B)-(D) of the Collaboration Agreement with respect to audit procedures. 
  

 9Amendment to the Sanofi Amendment Agreement, dated October 9, 2008

 Exhibit 10.59 
 CONFIDENTIAL TREATMENT REQUESTED UNDER 
 17 C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 240.24b-2.

 [*****] INDICATES OMITTED MATERIAL THAT IS THE 
 SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST 
 FILED SEPARATELY WITH THE COMMISSION. 
 THE OMITTED MATERIAL HAS BEEN FILED 
 SEPARATELY
WITH THE COMMISSION. 
 Thomas M. Finn 
 President, Global Healthcare 
 The Procter & Gamble Company 
 8700 Mason Montgomery Road 
 Mason, OH 45040 
 October 9, 2008 
 Re: Amendment Agreement
between The Procter & Gamble Company, Procter & Gamble Pharmaceuticals, Inc. (collectively, “P&G”), and Sanofi-Aventis U.S. LLC (“Sanofi-Aventis”), (individually P&G and Sanofi-Aventis may also be
referred to in this letter as “Party” and collectively as the “Parties”), dated December 19, 2007 (the “Amendment Agreement”). Capitalized terms used and not otherwise defined in this letter shall have the meanings
set forth in the Amendment Agreement or in the Amended and Restated Collaboration Agreement by and between The Procter & Gamble Company, Procter & Gamble Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC, dated October 8, 2004
(the “Collaboration Agreement”). 
 Dear Mr. Finn: 
 After execution of the Amendment Agreement (attached to this letter as Attachment A) on December 19, 2007, P&G and Sanofi-Aventis reached further agreement with respect to certain issues related
to the definition of Investment Costs, application of the Investment Cap, the Actonel® collaboration in the United Kingdom (the “UK”) during Contract Year 2008, and the addition of the UK to the P&G Promotion Territory as on
January 1, 2009, and the Parties wish to amend and supplement the Amendment Agreement related thereto as follows: 
 Section 1 of the
Amendment Agreement shall be deleted and replaced in its entirety with the following: 
 1. European Simplification: 

The Parties agree that their respective rights and obligations with respect to the Product in the European countries of Belgium, Germany, Luxembourg, The
Netherlands, and the United Kingdom shall be revised as set forth in Exhibit A, attached to and made a part of this Agreement. For purposes of this Agreement and consistent with the Collaboration Agreement, the Parties acknowledge and agree that any
reference to “Belgium” in this Agreement shall include the same understanding for the country of Luxembourg. 
  

 1 

 2. Section 1 of Exhibit A to the Amendment Agreement shall be deleted and replaced in its entirety with
the following: 
 Establishment of P&G Promotion Territory. 
 (a) General. The Parties shall use reasonable efforts to enable P&G to assume full responsibility for management and execution of Promotional Efforts, Marketing Efforts and R&D Efforts in
the following countries, on the dates indicated or as soon as reasonably possible thereafter as mutually agreed by the Parties, and such countries upon P&G’s assumption of full responsibility shall be considered part of the “P&G
Promotion Territory”: Germany, Belgium and Luxembourg, on and after January 1, 2008; and The Netherlands, on and after April 1, 2008 or sooner if mutually agreed by the Parties. 
 (b) United Kingdom. 
 (i)
The Parties shall use reasonable efforts to enable P&G to assume full responsibility for management and execution of Promotional Efforts, Marketing Efforts and R&D Efforts in the UK, on January 1, 2009, and upon such date, the UK shall
be considered part of the P&G Promotion Territory. Subject to Sections 4(a), 4(b)(i) and 4(b)(ii) below, from and after January 1, 2009 (1) the provisions included in Section 4 of this Exhibit A with respect to expense sharing
shall include the UK and the Investment Cap defined and further described in such Section 4 below shall include and be applicable to the promotion of Product in the UK; and (2) the provisions of Section 8 of this Exhibit A shall apply
to the UK. 
 3. Sections 4(a) and 4(b) of Exhibit A to the Amendment Agreement shall be deleted and replaced in their entirety with the
following: 
 4. Expense Sharing. 
 (a) General. The Parties have agreed to a maximum annual threshold or cap for the Investment Costs that may be incurred by P&G in the P&G Promotion Territory in each of Contract Years 2008,
2009 and 2010, and that may be incurred by both Parties in the UK in Contract Year 2008, as follows: (i) ***** of the sum of (1) the total actual NOS for all countries in the P&G Promotion Territory plus (2) the actual NOS for the
UK, for Contract Year 2008; (ii) ***** of the total actual NOS for all countries in the P&G Promotion Territory for Contract Year 2009; and (iii) ***** of the total actual NOS for all countries in the P&G Promotion Territory for
Contract Year 2010 (the “Investment Cap”). Consistent with the terms of the Collaboration Agreement, the Parties shall share ***** the actual Investment Costs incurred by P&G in the P&G Promotion Territory, and shall also share
***** the actual Investment Costs incurred by both Parties in the UK for Contract Year 2008, as part of the global reimbursement calculated pursuant to Schedule II (B) of the Collaboration Agreement, subject to the Investment Cap as further
described in Subsection 4(b) immediately below. For purposes of this Agreement, “Investment Costs” shall mean the costs related to and included in the Promotion Efforts, Marketing Efforts and R&D Efforts that are included in the
Quarterly invoices and reimbursement calculated for the Co-Promotion Countries under the Collaboration Agreement as of the Effective Date of this Agreement. 
  

 2 

 (b) Application of the Investment Cap. The following shall apply with regard to the Investment Cap:

 (i) Contract Year 2008. With regard to Contract Year 2008, the Parties shall share ***** the lower of either
(1) the sum of the total actual Investment Costs incurred by P&G in all countries of the P&G Promotion Territory plus the total actual Investment Costs incurred by both Parties in the UK or (2) the Investment Cap for 2008;

 (ii) Contract Years 2009 and 2010. With regard to Contract Years 2009 and 2010, the Parties shall share *****
the lower of either (1) the total actual Investment Costs incurred by P&G in all countries of the P&G Promotion Territory in the applicable Contract Year, or (2) an amount equal to the corresponding Investment Cap for such
Contract Year. If the Investment Cap is applied in a given Contract Year, then P&G shall be solely responsible for any of its Investment Costs that exceed the amount equal to the Investment Cap for such Contract Year; 
 (iii) Unusual Event. If an event occurs that is unusual and could not reasonably have been foreseen or anticipated by P&G,
and where, in each instance, such event can reasonably be expected to substantially impact P&G’s ability to reasonably maintain its Investment Costs in the P&G Promotion Territory below the Investment Cap in a particular Contract Year
(the “Unusual Event”), then (x) as soon as reasonably practical, the Parties shall discuss potential reasonable solutions to address the Unusual Event and P&G’s Investment Costs that exceed the Investment Cap;
(y) P&G shall take all reasonable actions to implement such mutually agreed solutions or to mitigate its Investment Costs in response to the Unusual Event, as applicable; and (z) the Parties shall share ***** the actual Investment
Costs incurred by P&G as a result of the Unusual Event, including those that may exceed the Investment Cap, for such time as P&G incurs such additional Investment Costs, but in no event for longer than a period of three (3) consecutive
months after the occurrence of the Unusual Event; 
 (iv) Level of Investment Cap. In the event the Investment Cap
is applied in a given Contract Year as described in Subsections 4 (b)(i)-(ii) above, then the Parties shall in good faith discuss the Investment Costs and Investment Cap anticipated for the subsequent Contract Years after the Contract Year when
the Investment Cap is applied, and may mutually agree to adjust the Investment Cap for the subsequent Contract Years; and, 
 (v) Level of Investment Costs. In October of Contract Year 2008 as part of the budget and forecast planning process for Contract Year 2009 under the Collaboration Agreement, the Parties agree to conduct a good faith discussion
regarding the level of Investment Costs that may be commercially reasonable and necessary in order for P&G to promote Product in the P&G Promotion Territory in Contract Years 2009 and 2010; provided that, if the parties do not agree
to revise the level of such Investment Costs then the Investment Caps for such Contract Years shall remain as set forth in Section 4(a) of this Exhibit A. 
 4. The following subparagraph (d) shall be appended to the end of Section 7 of Exhibit A to the Amendment Agreement: 
 (d) United Kingdom 
  

	 	•	 	 S-A will ***** Detailing Efforts on May 1, 2008. 

  

	 	•	 	 S-A will communicate to P&G by May 30, 2008 important sales information such as pending actions or meeting dates agreed at territory level by
S-A Representatives or other commitments towards third parties which have not been closed out by S-A sales forces or others at S-A providing sales support services. 

  

 3 

	 	•	 	 S-A will stop clinical promotion through its Dispensing Doctor channel team as of May 1, 2008. S-A will stop taking commercial orders
through such team on December 31, 2008. 

  

	 	•	 	 S-A’s Actonel Hospital Contract Team will continue to manage contracts with applicable hospital customers until P&G assumes
responsibility for this effort, no later than December 31, 2008. 

  

	 	•	 	 S-A will continue to provide Marketing Efforts until June 15, 2008, and will provide P&G with all reasonably necessary information relating to
such Marketing Efforts, including pending projects, deadlines, agency contracts, and work that is ongoing under purchase orders, prior to that date. 

  

	 	•	 	 S-A will continue to provide market research efforts until June 30, 2008, and will specifically deliver the ***** for May and June 2008 and will
transition ad hoc research (e.g., ***** to P&G in a timely fashion. 

  

	 	•	 	 S-A will review with P&G the costs associated with S-A’s Promotion Efforts, Marketing Efforts, and R&D Efforts, by June 15, 2008.
Such costs will be shared as part of the Global Payment made for the second Quarter of Contract Year 2008, to cover all investments on the ledger as of June 30, 2008. 

  

	 	•	 	 Both parties will refrain from proactive external communications regarding the transfer of responsibilities between S-A and P&G, unless any such
communications are mutually agreed in writing. 

  

	 	•	 	 S-A will discontinue order, shipping, and billing services for the Product on December 31, 2008, and prior to that date S-A will provide to
P&G a summary of any issues regarding such services. 

  

	 	•	 	 S-A will transfer to P&G those documents relevant to the approval of promotional material for the Product by May 1, 2008, as more specifically
agreed by the Parties’ respective medical teams. 

  

	 	•	 	 S-A will transfer files related to any present and past advertising challenges related to the Product or its promotion by May 1, 2008, as needed
by P&G, as P&G is in possession of all such materials as the holder of all Health Registrations in the UK. 

  

	 	•	 	 S-A and P&G will agree to a plan, on an as-needed basis, for the handling of adverse events reports and medical communication requests for events
that occur after June 30, 2008, as P&G currently handles all such inquiries and communications as the holder of all Health Registrations in the UK pursuant to the local Marketing Services Agreement. 

  

	 	•	 	 S-A will provide P&G with a written summary of, and will transfer responsibility to P&G for, the ***** by June 30, 2008.

  

	 	•	 	 S-A will make the final payments related to the *****, including payment of the final invoice for £10,000 from agreed budgets. P&G will work
with ***** to obtain the final results of such study. 

  

	 	•	 	 S-A will work with ***** to finalise the ***** and make all related payments, by June 30,2008. 

  

	 	•	 	 Other transition services reasonable, customary and necessary to facilitate the inclusion of the UK in the P&G Promotion Territory, including but
not limited to, the sharing of documents, making available samples, sales and promotional materials, and training materials, and as appropriate transferring any other ongoing clinical studies, grants, etc. 

  

 4 

 5. For clarification purposes and to correct a drafting error in the text, Section 3(A)(2) of the
Amendment Agreement shall be amended as follows: (a) to delete the phrase “within five (5) Business Days of such decision of the applicable U.S. federal court,” and to replace it with “pursuant to the payment terms described
in the last sentence of this Section 3(A)(2);” and (b) the reference to “Section 3(A)(3)” in the last sentence of this Section 3(A)(2) shall be deleted and replaced by the correct reference of “Section
3(A)(2)”. 
 6. Except as specifically agreed by the Parties in this letter, the terms and conditions of the Amendment Agreement shall
remain in full force and effect. 
 IN WITNESS WHEREOF, P&G and Sanofi-Aventis have caused this letter amendment to the
Amendment Agreement to be executed by their duly authorized representatives as of the date of this letter first written above. 
  

									
	The Procter & Gamble Company	 		 	Sanofi-Aventis U.S. LLC
					
	By:	 	 /s/ Thomas M. Finn
	 		 	By:	 	 /s/ Gregory Irace

	Name:	 	Thomas M. Finn	 		 	Name:	 	Gregory Irace
	Title:	 	President, Global Health	 		 	Title:	 	President & CEO
				
	Procter & Gamble Pharmaceuticals, Inc	 		 		 	
					
	By:	 	 /s/ Thomas M. Finn
	 		 		 	
	Name:	 	Thomas M. Finn	 		 		 	
	Title:	 	President	 		 		 	

  

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]